Andrew Powrie-Smith added:
“On announcing the deal, the First Minister stated that investments like this highlight the combined strength of our academic and commercial sectors, and the ABPI echoes this. With three-quarters of the £100 million investment figure coming from pharmaceutical companies, it shows just what Scotland can achieve when the different stakeholders work together in partnership.
“It is an exciting period when it comes to new medicines in Scotland, with both the Scottish Parliament’s Health & Sport Committee’s inquiry and the Scottish Government’s independent review of new medicine processes due to report in the coming weeks.
“Such a tangible demonstration of the potential for Scotland in new medicines discovery is therefore very timely, and I hope that both reviews will make strong recommendations to improve the processes we have in Scotland to allow more patients to get access to new medicines. It would be unfortunate if cutting edge medicines were being discovered in Scotland, only for Scottish patients to be denied access to them.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.